No. | | Times Cited: |
|---|
1. | Motzer RJ, Michaelson MD, Redman BG, et al.
Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
JOURNAL OF CLINICAL ONCOLOGY 24 (1): 16-24 JAN 1 2006 | 343 |
2. | Motzer RJ, Hutson TE, Tomczak P, et al.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
NEW ENGLAND JOURNAL OF MEDICINE 356 (2): 115-124 JAN 11 2007 | 260 |
3. | Wallace DC A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine ANNUAL REVIEW OF GENETICS 39: 359-407 2005 | 247 |
4. | Escudier B, Eisen T, Stadler WM, et al.
Sorafenib in advanced clear-cell renal-cell carcinoma
NEW ENGLAND JOURNAL OF MEDICINE 356 (2): 125-134 JAN 11 2007 | 246 |
5. | Ratain MJ, Eisen T, Stadler WM, et al.
Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma.
JOURNAL OF CLINICAL ONCOLOGY 24 (16): 2505-2512 JUN 1 2006 | 222 |
6. | Motzer RJ, Rini BI, Bukowski RM, et al.
Sunitinib in patients with metastatic renal cell carcinoma.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 295 (21): 2516-2524 JUN 7 2006 | 210 |
7. | Dannull J, Su Z, Rizzieri D, et al.
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
JOURNAL OF CLINICAL INVESTIGATION 115 (12): 3623-3633 DEC 2005 | 196 |
8. | Baselga J, Arteaga CL
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
JOURNAL OF CLINICAL ONCOLOGY 23 (11): 2445-2459 APR 10 2005 | 192 |
9. | Weiss G, Goodnough LT Medical progress: Anemia of chronic disease NEW ENGLAND JOURNAL OF MEDICINE 352 (10): 1011-1023 MAR 10 2005 | 178 |
10. | Jain RK, Duda DG, Clark JW, et al.
Lessons from phase III clinical trials on anti-VEGF therapy for cancer.
NATURE CLINICAL PRACTICE ONCOLOGY 3 (1): 24-40 JAN 2006 | 174 |
